PMID- 34218545
OWN - NLM
STAT- MEDLINE
DCOM- 20220209
LR  - 20221207
IS  - 2191-0286 (Electronic)
IS  - 0792-6855 (Linking)
VI  - 33
IP  - 1
DP  - 2021 Jul 2
TI  - A new application of mTOR inhibitor drugs as potential therapeutic agents for 
      COVID-19.
PG  - 17-25
LID - 10.1515/jbcpp-2020-0495 [doi]
AB  - Since December 2019, the COVID-19 emerging pandemic caused by SARS-CoV-2 has 
      resulted in one of the most important global health threats. Concerning the 
      absence of an approved effective vaccine or drug for the treatment and outcome 
      improvement of COVID-19 patients, and the role of SARS-CoV-2 in activation of 
      mammalian target of rapamycin (mTOR) pathway, we decided to review the previous 
      data regarding the therapeutic effect of mTOR inhibitor drugs in COVID-19 
      patients. We searched the scientific databases such as Web of Science, Embase, 
      Medline (PubMed), Scopus, and Google Scholar using appropriate keywords to find 
      suitable studies or suggestions until October 2020. The findings of the current 
      study confirmed that mTOR inhibitor drugs through suggested mechanisms such as T 
      cell adjustment, induction of autophagy without apoptosis, reduction of viral 
      replication, restoration of the T-cell function, decrease cytokine storm, and 
      moderation of the mTOR-PI3K-AKT pathway activation bring about a therapeutic 
      impact in COVID-19 patients. Taken together, it is necessary to find a suitable 
      therapy for the COVID-19 pandemic emerging. In this regard, we clarify that it is 
      valuable to consider the therapeutic effect of mTOR inhibitor drugs and metformin 
      by its mTOR inhibition property in the treatment of COVID-19 patients.
CI  - (c) 2021 Walter de Gruyter GmbH, Berlin/Boston.
FAU - Mashayekhi-Sardoo, Habibeh
AU  - Mashayekhi-Sardoo H
AUID- ORCID: 0000-0002-7334-5603
AD  - Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad 
      University of Medical Sciences, Mashhad, Iran.
FAU - Hosseinjani, Hesamoddin
AU  - Hosseinjani H
AUID- ORCID: 0000-0002-1482-871X
AD  - Department of Clinical Pharmacy, School of Pharmacy, Mashhad University of 
      Medical Sciences, Mashhad, Iran.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210702
PL  - Germany
TA  - J Basic Clin Physiol Pharmacol
JT  - Journal of basic and clinical physiology and pharmacology
JID - 9101750
RN  - 0 (Antiviral Agents)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Antiviral Agents/*pharmacology
MH  - Humans
MH  - Pandemics
MH  - SARS-CoV-2/drug effects
MH  - TOR Serine-Threonine Kinases/*antagonists & inhibitors
MH  - *COVID-19 Drug Treatment
OTO - NOTNLM
OT  - COVID-19
OT  - SARS-CoV-2
OT  - coronavirus
OT  - mTOR inhibitors
OT  - metformin
OT  - rapamycin
OT  - sirolimus
EDAT- 2021/07/05 06:00
MHDA- 2022/02/10 06:00
CRDT- 2021/07/04 21:17
PHST- 2020/12/04 00:00 [received]
PHST- 2021/06/01 00:00 [accepted]
PHST- 2021/07/05 06:00 [pubmed]
PHST- 2022/02/10 06:00 [medline]
PHST- 2021/07/04 21:17 [entrez]
AID - jbcpp-2020-0495 [pii]
AID - 10.1515/jbcpp-2020-0495 [doi]
PST - epublish
SO  - J Basic Clin Physiol Pharmacol. 2021 Jul 2;33(1):17-25. doi: 
      10.1515/jbcpp-2020-0495.